dabigatran has been researched along with imatinib mesylate in 2 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | dabigatran (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariano, C; De Vecchis, R | 1 |
| Bertoletti, L; Bin, V; Delavenne, X; Hodin, S; Lafaie, L; Saïb, S | 1 |
2 other study(ies) available for dabigatran and imatinib mesylate
| Article | Year |
|---|---|
Network meta-analysis: a new analysis tool of the experimental evidence.
Topics: Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Dabigatran; Dasatinib; Data Interpretation, Statistical; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Warfarin | 2019 |
Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein.
Topics: Administration, Oral; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Axitinib; Crizotinib; Dabigatran; Drug Interactions; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Rivaroxaban | 2022 |